Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Researchers at Tel Aviv University have achieved a breakthrough in drug delivery: they have successfully transported lipid ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

New research reveals that sunburn may be caused by RNA damage, not DNA, challenging long-held beliefs about UV exposure ...

The human genome encodes potentially thousands of tiny proteins that were previously overlooked. The search is on to find out ...

Using a single-cell sequencing technique, Brazilian researchers have created the first cell atlas of focal cortical dysplasia ...

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...

Intuit Inc. , the global financial technology platform that makes TurboTax, Credit Karma, QuickBooks, and Mailchimp, will announce its second-quarter financial results for fiscal year 2025 on February ...

Neurocrine Biosciences, Inc. announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time ...